Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
about
Modes of resistance to anti-angiogenic therapyAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsPersonalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and TaxolMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaLenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerThe CXCL8-CXCR1/2 pathways in cancerOncologic Angiogenesis Imaging in the clinic---how and why.Discovery of a novel class of AKT pleckstrin homology domain inhibitors.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsAdverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.Regulation of tumor angiogenesis by EZH2.Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulvenSunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.VEGF blocking therapy in the treatment of cancer.Molecular targets in the inhibition of angiogenesis.RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics.Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast CancerTumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapyTransforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG.The potential of positron-emission tomography to study anticancer-drug resistance.Diversity of the angiogenic phenotype in non-small cell lung cancer.Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.Reversing resistance to targeted therapy.Antiangiogenic therapy in human gastrointestinal malignancies.Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice.Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment.Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamicsDll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.Inhibition of angiogenesis and invasion in malignant gliomas.Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinomaDevelopment of antiangiogenic agents for ovarian cancer.Therapeutic approaches to target cancer stem cells.Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.VEGF Trap induces antiglioma effect at different stages of disease.GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis.
P2860
Q24608005-9298C330-4246-4C54-9E8E-E461D002F7FDQ24608039-4A0087CA-E083-477C-A045-61E7D2574788Q26773795-4642D746-B6C6-45DD-A359-08A2672C9AC9Q26784219-4BDFAAD7-D093-4945-A4E3-C210796A3D33Q27021470-D5BE03CF-A57C-44E8-8F8E-EF9F62A6F927Q28072655-41BEB7A9-1B8B-4465-BEB5-A2118A14A6B7Q28075994-09334158-6632-43FB-9BA4-DAB450126996Q30472751-8B43BA6D-741C-4001-ABD5-8195761C2BDEQ33369369-564D210C-FE0E-4EB5-9C0D-FC1540E87544Q33409319-A3CD2D65-F2F1-43AD-9058-7B6C4F8F7BC1Q33410375-24F1B4AF-0ECB-47D2-BE37-C4691A168B0CQ33824587-AC7A178B-ED35-40CE-B5D1-8A066D593E2FQ33882138-E37F225E-C6C1-4233-8824-D1FAF7908286Q34039409-4D919970-F667-49FD-9A26-E862F7F5CF4CQ34073170-24245430-6802-4E79-A3B9-AAFA2106CAF2Q34589227-B0E8D537-EF94-4D34-8C22-966BE3D816DFQ35079536-5C13A5F8-4D1D-4B66-A9F5-EBA089DD14F7Q35093616-A449C17B-6366-49FF-B727-2162DC7FC545Q35186667-C480E0CD-E414-482E-9D92-4B5DA8031FF4Q35622886-6F0B8C8B-3204-4878-A59E-F9C51F470AA1Q35684466-8AFC36D0-7E41-415C-BAE4-19D7DC6E588CQ35748830-E2667C61-53ED-4738-826A-A9F0DF5D0065Q35760962-80674FF0-653D-4ADA-85EB-75F488D15FFAQ35788120-0B400BDC-5BFA-4785-BF10-5469C633EE7AQ35855285-3CADB8D9-53C1-447A-BFEA-705FC4A2A2ADQ35994847-A7BC8E70-291D-40A5-A195-818CACBB28A4Q36028603-79516D9B-E869-4BE2-BB30-7604BA932816Q36591067-0E3D82A0-B30D-4B73-B389-01EF5BB0A18DQ36670782-B15CB7CE-D4C1-4994-A410-B11BFEDE47E8Q36775480-4C195364-F27E-4BEA-8209-474F5640DA6CQ36928730-1E007D08-099F-49A6-8264-041030EE94E9Q36966669-67552DFC-604A-4B18-8936-1E443A297CDFQ36971300-3B650A2C-3056-4742-9F6F-016C71D880A1Q37004664-DD1D2250-45B6-4B4D-8B76-AEB398FC9DB4Q37035437-C7EBD4E2-AB5A-4B4C-AF93-A479AE13771BQ37038884-3DCD45DA-926E-456E-A3D1-4803F5C26DF3Q37137412-7E6E2BE2-7160-45E1-BD21-AD999348C63BQ37260842-114231A2-D108-4096-B214-FDAF2BBC71B9Q37284357-411A4134-DF16-4F85-9725-7A52540FB39CQ37392845-EF4B3E51-196F-4CE4-A6FA-7B9BE6C04F95
P2860
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Possible mechanisms of acquire ...... ombination therapy approaches.
@ast
Possible mechanisms of acquire ...... ombination therapy approaches.
@en
Possible mechanisms of acquire ...... ombination therapy approaches.
@nl
type
label
Possible mechanisms of acquire ...... ombination therapy approaches.
@ast
Possible mechanisms of acquire ...... ombination therapy approaches.
@en
Possible mechanisms of acquire ...... ombination therapy approaches.
@nl
prefLabel
Possible mechanisms of acquire ...... ombination therapy approaches.
@ast
Possible mechanisms of acquire ...... ombination therapy approaches.
@en
Possible mechanisms of acquire ...... ombination therapy approaches.
@nl
P2093
P356
P1476
Possible mechanisms of acquire ...... combination therapy approaches
@en
P2093
A Viloria-Petit
R S Kerbel
P2888
P356
10.1023/A:1013172910858
P577
2001-01-01T00:00:00Z
P6179
1050001380